Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;21(16):1955-1964.
doi: 10.1080/14656566.2020.1799977. Epub 2020 Aug 18.

Ponesimod for the treatment of relapsing multiple sclerosis

Elisa Baldin  1 , Alessandra Lugaresi  2   3
Affiliations
Review

Ponesimod for the treatment of relapsing multiple sclerosis

Elisa Baldin et al. Expert Opin Pharmacother. 2020 Nov.

Abstract

Introduction: Multiple Sclerosis (MS) is an immune-mediated, complex, chronic inflammatory, and neurodegenerative disease of the central nervous system. Among the several therapeutic options developed over the last decade for relapsing MS (RMS), fingolimod, a sphingosine 1-phosphate receptor (S1PR) modulator, was the first oral treatment. The adverse events associated with fingolimod have limited its use in certain populations, thus further stimulating the search for other S1PR modulators.

Areas covered: The authors reviewed the English-published literature on ponesimod using the PubMed database. The search terms used were 'ponesimod' or 'ACT-128,800' and 'multiple sclerosis.' Available data on the pharmacological profile of ponesimod and the information on clinical efficacy and safety drawn from clinical trials in comparison with other S1PR modulators are presented and discussed.

Expert opinion: Published peer-reviewed data on long-term safety and efficacy are still lacking but have been collected and regulatory authorities expressed a favorable opinion to market access. At present, we believe that ponesimod has little chance of becoming a leading treatment for RMS due to the availability of many alternative options and the timing of market access. Given its favorable risk-benefit and convenience profile, however, ponesimod might become a leading option among S1P receptor modulators used for RMS.

Keywords: ACT-128,800; disease-modifying therapies; efficacy; multiple sclerosis; ponesimod; risk-benefit; safety; sphingosine-1-phosphate modulator; tolerability.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources

-